Emergent Biosolutions
EBS
EBS
276 hedge funds and large institutions have $2.22B invested in Emergent Biosolutions in 2021 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 110 increasing their positions, 96 reducing their positions, and 33 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
21% less capital invested
Capital invested by funds: $2.8B → $2.22B (-$580M)
33% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 33
Holders
276
Holding in Top 10
1
Calls
$5.88M
Puts
$5.79M
Top Buyers
| 1 | +$17.5M | |
| 2 | +$17M | |
| 3 | +$16.5M | |
| 4 |
State Street
Boston,
Massachusetts
|
+$13.7M |
| 5 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$7.57M |
Top Sellers
| 1 | -$39M | |
| 2 | -$26.6M | |
| 3 | -$15.6M | |
| 4 |
Two Sigma Advisers
New York
|
-$12.4M |
| 5 |
Morgan Stanley
New York
|
-$8.36M |